In the pivotal trial, the addition of polatuzumab vedotin to bendamustine and rituximab (Pola-BR) improved overall survival (OS) for stem cell transplant (SCT)-ineligible patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). However, the optimal position of Pola-BR in the treatment pathway for patients who receive it as a ‘stand-alone’ treatment, without planned SCT consolidation or CAR T-cell therapy, remains an open question. 71% of patients in the pivotal trial received Pola-BR in 3rd line or beyond but detailed analysis of outcomes by lines of therapy were not presented and published real-world data for this cohort are lacking. We previously reported results of our real-world study of Pola-BR and we now present further analysis of efficacy according to prior treatment exposure. Methods: Retrospective data were collected for consecutive patients treated with Pola-BR at 28 UK hospitals via the UK Regulatory Agency’s Early Access to Medicines Scheme (EAMS) which ran from June 2019 to Jan 2020 prior to marketing authorisation. Patients with R/R LBCL after ≥1 prior treatment were eligible. Treatment was administered according to the marketing authorisation, dose reductions or delays were permitted according to physicians’ discretion. Responses were investigator assessed, time to event was measured from the start of Pola-BR. Results: Pola-BR was administered as stand-alone treatment for 76 of 106 patients who received it via EAMS, treatment intent for the remaining patients was bridge to CAR-T or SCT. Of the stand-alone cohort, 43 received it 2nd line (2L) and 33 at 3rd line or later (≥3L). The median age was 75 years (range 41-88), 71.1% were male. Patients in the ≥3L group were younger and tended to have later stage disease, other characteristics including sex, performance status, IPI and the presence of bulk were well balanced between the groups. 55.8% and 57.6% respectively, were refractory to their last treatment. The objective response rates (ORR) were 73.2% (95% CI 57.1–85.8) and 54.5% (95% CI 36.4%-71.9%) for the 2L and ≥3L groups respectively (p = 0.1). The complete response (CR) rates were 48.8% (32.9–64.9) and 30.3% (15.6-48.7) (p = 0.1). A best response of progressive disease to Pola-BR was found for 22.0% and 36.4% in the 2L and ≥3L groups respectively. The 6-month progression free survival (PFS) rates were 54.2% (95% CI 37.9–67.9) and 35.9% (95% CI 20.1–52.0) for the 2L and ≥3L groups respectively (HR 2.17 (95% CI 1.19–3.95), p = 0.01). The 6-month OS rate was 68.4% (95% CI 51.8–80.4) in the 2L group and 49.2% (95% CI 30.9–65.2) in the ≥3L group (HR 2.15 (95% CI 1.12–4.14), p = 0.02). Longer follow up will be presented. Keywords: aggressive B-cell non-Hodgkin lymphoma, combination therapies Conflicts of interests pertinent to the abstract W. Osborne Honoraria: Roche R. Auer Honoraria: Beigene C. Burton Honoraria: Roche A. Davies Consultant or advisory role: Celgene, Roche, Gilead, Incyte, Abbvie Honoraria: Celgene, Roche, Gilead, Janssen, Acerta Pharma/AstraZeneca, ADC Therapeutics, Incyte, Abbvie Research funding: Celgene, Roche, Gilead, Janssen, Acerta Pharma/AstraZeneca, ADC Therapeutics, BioInvent Educational grants: Celgene, Roche D. El-Sharkawi Honoraria: Roche Educational grants: Roche C. Fox Consultant or advisory role: Abbvie, AstraZeneca, Atarabio, BMS, GenMab, Gilead/Kite, Incyte, Lilly, Morphosys, Ono, Roche, Takeda Research funding: Beigene Educational grants: Roche, BMS A. Kuhnl Consultant or advisory role: Kite/Gilead, Novartis, BMS Honoraria: Kite/Gilead, Novartis, BMS P. McKay Honoraria: Roche E. Phillips Honoraria: Takeda, Gilead Educational grants: Celgene, Takeda, Janssen W. Townsend Consultant or advisory role: Roche, Takeda, Gilead, Incyte, Honoraria: Roche, Gilead, Incyte Educational grants: Roche, Takeda